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Investigation of the adenosine A(2A) receptor on the enhanced rewarding effects of nicotine and
dopamine D2 receptor signaling in a novel heritable model of drug abuse vulnerability
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Department of Biomedical Sciences, Quillen College of Medicine, East Tennessee State University, Johnson City, TN.
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Dopamine D2-A2A heteromer and pathway

Figure 2. Sensorimotor gating test

Psychosis is a characteristic of several behavioral and
neurological disorders, including schizophrenia, bipolar
disorder, and obsessive-compulsive disorder [1].
All of these disorders have presented with increases in
dopamine D2 (DAD2) receptor sensitivity [2].
Substance abuse comorbidity is common in all of these
disorders, especially an increase in cigarette smoking [3].
Disorders that present with increased DAD2 sensitivity and
substance abuse have a hereditary component [4].
In past work, we have shown increases in DAD2 sensitivity
after neonatal quinpirole (DAD2 agonist) to rats [5].
We bred rats neonatally treated with quinpirole and tested the
offspring. These offspring have shown increases in DAD2
receptor sensitivity n this next (F1) generation [6].
Since DAD2 receptors form mutually inhibitory heteromers in
the brain with adenosine A(2A) receptors, we analyzed
whether an adenosine A(2A) agonist, CGS 21680, would block
both enhanced responses to nicotine and sensorimotor gating
deficits that occur in these animals.

Methods
• Rats neonatally treated with quinpirole HCl (1 mg/kg) or saline were grown to
postnatal day 60 (P60) and bred. Their offspring were used as subjects.
• Conditioned place preference (CPP): a three chambered apparatus was used
(See Figure 1).
• All rats were administered two initial drug-free preference tests on P41 and P42
to determine initial context preference.
• Conditioning began on P43 and ran through P50 (eight days total), with the
dividers placed into the apparatus and the assignment of each context
randomized across subjects.
• Conditioning consisted of two trials per day, an AM trial and a PM trial.
• AM session: All rats were IP administered saline and placed into their assigned
context for a 10 min trial.
• PM session: All rats were IP administered saline or nicotine (0.6 mg/kg free base;
SN) preceded by ip administration of saline (SS), or 0.09 mg/kg CGS 21680
(0.09CGS-N) and placed into the paired context for a 10 min trial.
• Post conditioning test was performed on P51 identical to pre-conditioning
preference tests on P41-42.Dependent measure was the mean percent time
spent in the paired context on the pre-conditioning trial subtracted away from
mean percent time spent in the paired context on the post-conditioning test.
• Prepulse Inhibition: Each daily session began with a 5-minute habituation
period with only background noise present (70 dB).
• Animals were administered three different, randomly-assigned trial types (pulse,
prepulse, no stimulus). A pulse trial was a 120 dB startle pulse administered
alone. A Prepulse trial was a stimulus 3, 6, or 12 dB above background noise. A
No stimulus trial a stimulus was not presented. The response measured within a
250 ms window immediately following stimulus presentation.
• RGS9, β arrestin-2, and phospho-AKT were all analyzed with commercially
available ELISA kits (Biomatik, Wilmington, DE; MyBioSource.com, San Diego,
CA) in the dorsal striatum because it is heavily innervated by dopamine.
• Table 1: Group Codes.
Treatment of Founders

Group Code

NQ Male (MQ), NQ Female (FQ)

F1 MQ x FQ

NQ Male (MQ), NS Female (FS)

F1 MQ x FS

NS Male (MS), NQ Female (FQ)

F1 MS x FQ

NS (Neonatal Saline)

F0 NS

Conclusions
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•
•
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•
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Representation of the A2A-DAD2 pathway. In blue is RGS9, which is Gprotein dependent; in red is the G-protein independent pathway

•

Figure 1. Nicotine CPP

A dose of 0.09 mg/kg CGS 21680 (CGS) alleviated deficits in
PPI in both F1 MQxFQ and F1 MSxFQ groups. CGS groups
were equivalent to controls (F0 NS) and greater than salinetreated F1 generation animals (indicated by *, p<.05).

Figure 3. Dopamine D2 signaling in striatum

•

Administration of the adenosine A(2A) agonist CGS 21680
reduced the enhanced response to nicotine in F1 generation
offspring of NQ-treated rats.
Likewise, administration of CGS 21680 was effective to alleviate
PPI deficits in F1 generation offspring of NQ-treated rats.
Both nicotine CPP and sensorimotor gating deficits share a
common substrate: An increase in dopaminergic activity,
especially in the forebrain.
These data suggest that treatment of both substance
abuse comorbidity and psychosis may be a single
pharmacological target, the adenosine A(2A) receptor.
Notably, there is a hypothesis that adenosine dysregulation
precedes the changes in dopamine D2 receptor sensitivity in
schizophrenia, which has been termed the ‘adenosine
hypothesis of psychosis’[7].
These results demonstrate that the adenosine A(2A) receptor is
a potential target for the treatment of nicotine abuse comorbidity
as well psychosis in behavioral disorders that present with
increases in DAD2 receptor sensitivity.
Future studies will:
1. Investigate the use of an adenosine A(2A) agonist as an
adjunctive with an antipsychotic in behavioral tests with
relevance to treatment of psychosis and substance
abuse.
2. Investigate neural plasticity markers involved in cell
growth in brain areas heavily innervated by the dopamine
neurotransmitter.
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